{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:10:23Z","timestamp":1771305023900,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>The aim of this survey of psychiatrists from the UK and India was to compare their opinions on antipsychotic medication choice and their experiences of such medications\u2019 effectiveness and tolerability in patients who were newly diagnosed with acute schizophrenia. Following ethical approval, a cross-sectional online survey of psychiatrists from the UK and India was conducted. Ninety-five responses were received from each country. The most selected first-line APDs in both countries were olanzapine (47.5%), risperidone (42.8%) and aripiprazole (25.3%). A total of 60% of psychiatrists from India (60%) and 48% from the UK (48%) selected \u2018medication efficacy\u2019 as the main factor in their choice. Reassessment and consideration to switch most often took place within 4\u20136 weeks (53.7%) and 3\u20136 months (11.6%). The major reasons for switching antipsychotic medications were poor clinical efficacy (69%) and lack of tolerability (45%). Nonadherence was the most common reason for relapse (90% of UK psychiatrists and 70% of Indian psychiatrists), followed by illicit drug use (27.6%). The most commonly reported side effects that led to nonadherence were weight gain (10.8%), drowsiness (10.4%), erectile dysfunction and movement disorders (equally 8.7%). It was concluded that olanzapine, risperidone and aripiprazole are the most commonly selected as the initial treatment choice by psychiatrists from India and the UK. They are perceived as widely effective and well tolerated.<\/jats:p>","DOI":"10.3390\/pharmacy11050162","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T05:07:13Z","timestamp":1696828033000},"page":"162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom"],"prefix":"10.3390","volume":"11","author":[{"given":"Zina Sherzad","family":"Qadir","sequence":"first","affiliation":[{"name":"Research Institute in Health Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8801-9245","authenticated-orcid":false,"given":"Nilamadhab","family":"Kar","sequence":"additional","affiliation":[{"name":"Research Institute in Health Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK"},{"name":"Black Country Healthcare NHS Foundation Trust, Wolverhampton B71 4NH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Anthony","family":"Ball","sequence":"additional","affiliation":[{"name":"Research Institute in Health Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK"},{"name":"School of Dentistry & Medical Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9752-537X","authenticated-orcid":false,"given":"Hana","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Research Institute in Health Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"ref_1","unstructured":"NHS (2020, September 09). Treatment\u2014Schizophrenia London. UK: NHS UK. Available online: https:\/\/www.nhs.uk\/mental-health\/conditions\/schizophrenia\/treatment\/."},{"key":"ref_2","unstructured":"NICE (2020, September 09). Clinical Guidance CG178 Psychosis and Schizophrenia in Adults: Prevention and Management London: National Institute for Health and Care Excellence. 2014 [Updated 1 March 2014]. Available online: https:\/\/www.nice.org.uk\/guidance\/cg178\/evidence\/full-guideline-490503565."},{"key":"ref_3","unstructured":"BNF (2020, September 09). Psychoses and Related Disorders. London: Joint Formulary Committee. Available online: https:\/\/bnf.nice.org.uk\/treatment-summaries\/psychoses-and-related-disorders\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2471\/BLT.07.045377","article-title":"Schizophrenia treatment in the developing world: An interregional and multinational cost-effectiveness analysis","volume":"86","author":"Chisholm","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"ref_5","unstructured":"NICE (2020, September 09). Psychosis and Schizophrenia in Adults: Prevention and Management London: National Institute for Health and Care Excellence. 2014 [Updated 1 April 2014]. Available online: https:\/\/www.nice.org.uk\/guidance\/cg178."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106s","DOI":"10.1038\/sj.npp.1395370","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_9","unstructured":"POMH-UK (2020, September 09). Prescribing High Dose and Combined Antipsychotics on Adult Psychiatric Wards London UK: Prescribing Observatory for Mental Health, The Royal College of Psychiatrists. Available online: https:\/\/www.elft.nhs.uk\/sites\/default\/files\/2022-03\/POMH-UK%2BTopic%2B1g%2Band%2B3d%2Breport%2B-Trust%2B12.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psychres.2018.04.002","article-title":"Non-adherence to antipsychotic medication in first-episode psychosis patients","volume":"264","author":"Hickling","year":"2018","journal-title":"Psychiatry Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1192\/bjp.184.6.509","article-title":"Non-adherence to antipsychotic medication regimens: Associations with resource use and costs","volume":"184","author":"Knapp","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13643-018-0676-y","article-title":"Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: A protocol for a systematic review","volume":"7","author":"Semahegn","year":"2018","journal-title":"Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kadra-Scalzo, G., Fonseca de Freitas, D., Agbedjro, D., Francis, E., Ridler, I., Pritchard, M., Shetty, H., Segev, A., Casetta, C., and Smart, S.E. (2022). A predictor model of treatment resistance in schizophrenia using data from electronic health records. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0274864"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00406-019-01053-6","article-title":"Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: A chart review study","volume":"270","author":"Shah","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: A systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/eip.12385","article-title":"The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication","volume":"12","author":"Upthegrove","year":"2018","journal-title":"Early Interv. Psychiatry"},{"key":"ref_17","unstructured":"UK Government (2020, September 09). UK Population by Ethnicity London: UK Government 2011, Available online: https:\/\/www.ethnicity-facts-figures.service.gov.uk\/uk-population-by-ethnicity."},{"key":"ref_18","unstructured":"UK Government (2020, September 09). Population of England and Wales London: UK Government, Available online: https:\/\/www.ethnicity-facts-figures.service.gov.uk\/uk-population-by-ethnicity\/national-and-regional-populations\/population-of-england-and-wales\/latest."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.4103\/0019-5545.69195","article-title":"History of psychiatry in India","volume":"52","author":"Nizamie","year":"2010","journal-title":"Indian J. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/jmhhb.jmhhb_63_17","article-title":"Community Psychiatry in India: Where We Stand?","volume":"23","author":"Sidana","year":"2018","journal-title":"J. Ment. Health Hum. Behav."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/psychiatry.IndianJPsychiatry_102_17","article-title":"National Mental Health Survey of India 2015\u20132016","volume":"59","author":"Murthy","year":"2017","journal-title":"Indian J. Psychiatry"},{"key":"ref_22","unstructured":"National Institute of Mental Health and Neurosciences (NIMHANS) (2023, October 01). National Mental Health Survey of India, 2015\u20132016 Prevalence, Patterns and Outcomes. Available online: https:\/\/nimhans.ac.in."},{"key":"ref_23","unstructured":"Royal College of Psychiatrists (2020, September 09). Postcode Lottery for Psychiatric Care London: Royal College of Psychiatrists. Available online: https:\/\/www.rcpsych.ac.uk\/news-and-features\/latest-news\/detail\/2017\/09\/11\/postcode-lottery-for-psychiatric-care."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1108\/01443570210414310","article-title":"Survey research in operations management: A process-based perspective","volume":"22","author":"Forza","year":"2002","journal-title":"Int. J. Oper. Prod. Manag."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Cunningham, C.T., Quan, H., Hemmelgarn, B., Noseworthy, T., Beck, C.A., Dixon, E., Samuel, S., Ghali, W.A., Sykes, L.L., and Jett\u00e9, N. (2015). Exploring physician specialist response rates to web-based surveys. BMC Med. Res. Methodol., 15.","DOI":"10.1186\/s12874-015-0016-z"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pds.1126","article-title":"Response rates and representativeness: A lottery incentive improves physician survey return rates","volume":"14","author":"Robertson","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1097\/SLA.0000000000004078","article-title":"Global Overview of Response Rates in Patient and Health Care Professional Surveys in Surgery: A Systematic Review","volume":"275","author":"Meyer","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual. Res. Psychol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: Comparative effectiveness of first-generation versus second-generation medications: A systematic review and meta-analysis","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: A systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: A systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/0019-5545.86805","article-title":"State of Consultation-Liaison Psychiatry in India: Current status and vision for future","volume":"53","author":"Grover","year":"2011","journal-title":"Indian J. Psychiatry"},{"key":"ref_37","unstructured":"NHS (2020, September 09). NHS Prescription Charges London: NHS UK. Available online: https:\/\/www.nhs.uk\/nhs-services\/prescriptions-and-pharmacies\/nhs-prescription-charges\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1574886314666190301152734","article-title":"Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients","volume":"14","author":"Read","year":"2019","journal-title":"Curr. Drug Saf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/NDT.S339866","article-title":"Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists\u2019 Attitudes in Taiwan","volume":"18","author":"Yen","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.9758\/cpn.2021.19.4.610","article-title":"Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan","volume":"19","author":"Hatano","year":"2021","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajp.2017.08.002","article-title":"Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists\u2019 survey in India","volume":"30","author":"Gundugurti","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Eisner, E., Barrowclough, C., Lobban, F., and Drake, R. (2014). Qualitative investigation of targets for and barriers to interventions to prevent psychosis relapse. BMC Psychiatry, 14.","DOI":"10.1186\/1471-244X-14-201"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0920-9964(95)00108-5","article-title":"Relapse in schizophrenia: Is there a relationship to substance abuse?","volume":"20","author":"Gupta","year":"1996","journal-title":"Schizophr. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13651500510028995","article-title":"A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance","volume":"9","author":"MacE","year":"2005","journal-title":"Int. J. Psychiatry Clin. Pract."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/5\/162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:03:13Z","timestamp":1760130193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/5\/162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["pharmacy11050162"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy11050162","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]}}}